Trulicity vs Pomalyst
Side-by-side drug price comparison from Medicare Part D data
Verdict
Trulicity costs 97% less per claim than Pomalyst ($473.00 vs $17250.00). Neither drug has a generic alternative available. Total Medicare spending: Trulicity at $4.2B vs Pomalyst at $3.3B.
| Metric | Trulicity | Pomalyst |
|---|---|---|
| Avg Cost per Claim Average cost Medicare pays per prescription claim | $473* | $17,250 |
| Total Medicare Spending Total Medicare Part D spending on this drug | $4.2B | $3.3B |
| Total Claims | 8,920,000 | 192,000 |
| Year-over-Year Change Price change from prior year (lower is better for patients) | -4.8%* | 4.7% |
| Generic Available | No | No |
| Condition | Diabetes | Cancer |
| Total Beneficiaries | 985,000 | 18,000 |
Trulicity costs 97% less per claim than Pomalyst ($473.00 vs $17250.00). Neither drug has a generic alternative available. Total Medicare spending: Trulicity at $4.2B vs Pomalyst at $3.3B.
Explore More
Comparing Trulicity and Pomalyst on U.S. Medicare prescription-drug pricing requires lining up the underlying CMS Medicare Part D Drug Spending data data side by side. The table above runs the comparison on the canonical fields; the narrative below identifies the factor or factors that drive the most meaningful difference between the two.
Practical use of the comparison: read the data above, then drill into the individual Trulicity and Pomalyst detail pages for the underlying breakdown. A pairwise comparison answers the relative question; the per-entity pages answer the absolute question.
Source: CMS Medicare Part D Spending, 2026.